Polypharmacy in patients with advanced cancer and pain: A european cross-sectional study of 2282 patients

Journal of Pain and Symptom Management

Volumn 48, Issue 6, 2014, Pages 1145-1159

  Kotlinska Lemieszek, Aleksandra ^a,b   Paulsen, Ørnulf ^c,d   Kaasa, Stein ^d,f   Klepstad, Pål ^e,f  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Ginekologiczno Po o niczy Szpital Kliniczny im Heliodora wi cickiego Uniwersytetu Medycznego im Karola Marcinkowskiego   (Poland)

^c TELEMARK HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

adjuvants; cancer pain; coanalgesics; drug drug interactions; nonopioids; opioids; palliative care; Pharmacotherapy; polypharmacy; unnecessary drugs; unneeded drugs

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; LAXATIVE; MEGESTROL ACETATE; METOCLOPRAMIDE; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROTON PUMP INHIBITOR; PSYCHOSTIMULANT AGENT; SEROTONIN 3 ANTAGONIST; SPASMOLYTIC AGENT; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANESTHESIA COMPLICATION; ARTICLE; BLEEDING; CANCER PAIN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; EUROPE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; KIDNEY DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHARMACODYNAMICS; POLYPHARMACY; RESPIRATION DEPRESSION; RISK FACTOR; SEROTONIN SYNDROME; STOMACH ULCER; TORSADE DES POINTES; UPPER GASTROINTESTINAL BLEEDING; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CLINICAL TRIAL; INAPPROPRIATE PRESCRIBING; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PAIN; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHEMOTHERAPY, ADJUVANT; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; NEOPLASMS; PAIN; POLYPHARMACY; YOUNG ADULT;

EID: 84919845042     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2014.03.008     Document Type: Article

References (62)

1. F. Nauck, C. Ostgathe, E. Klaschik Working Group on the Core Documentation for Palliative Care Units in Germany Drugs in palliative care: results from a representative survey in Germany Palliat Med 18 2004 100 107
2. P. Klepstad, S. Kaasa, N. Cherny Research Steering Committee of the EAPC Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network Palliat Med 19 2005 477 484
3. D.C. Currow, J.P. Stevenson, and A.P. Abernethy Prescribing in palliative care as death approaches J Am Geriatr Soc 55 2007 590 595
4. T.I. Soh, Y.C. Yuen, and C. Teo Targeted therapy at the end of life in advanced cancer patients J Palliat Med 15 2012 991 997
5. D. Hui, M.S. Karuturi, and K.C. Tanco Targeted agent use in cancer patients at the end of life J Pain Symptom Manage 46 2013 1 8
6. M.J. Brennan The clinical implications of cytochrome P450 interactions with opioids and strategies for pain management J Pain Symptom Manage 44 2012 S15 S22
7. R.L. Maher, J. Hanlon, and E.R. Hajjar Clinical consequences of polypharmacy in elderly Expert Opin Drug Saf 13 2014 57 65
8. D.L. Vetrano, M. Tosato, and G. Colloca Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study Alzheimers Dement 9 2013 587 593
9. R.P. Riechelmann, F. Moreira, and E.D. Saad Potential for drug interactions in hospitalized cancer patients Cancer Chemother Pharmacol 56 2005 286 290
10. R.P. Riechelmann, I.F. Tannock, and L. Wang Potential drug interactions and duplicate prescriptions among cancer patients J Natl Cancer Inst 99 2007 592 600
11. R.P. Riechelmann Drug combinations with the potential to interact among cancer patients Support Care Cancer 15 2007 1113 1114
12. R.P. Riechelmann, and A. Del Giglio Drug interactions in oncology: how common are they? Ann Oncol 20 2009 1907 1912
13. V. Miranda, A. Fede, and M. Nobuo Adverse drug reactions and drug interactions as causes of hospital admission in oncology J Pain Symptom Manage 42 2011 342 353
14. J. Lees, and A. Chan Polypharmacy in elderly patients with cancer: clinical implications and management Lancet Oncol 12 2011 1249 1257
15. K.C. Sokol, J.F. Knudsen, and M.M. Li Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management J Clin Pharm Ther 32 2007 169 175
16. V. Girre, H. Arkoub, and M.T. Puts Potential drug interactions in elderly cancer patients Crit Rev Oncol Hematol 78 2011 220 226
17. A. Wilcock, J. Thomas, and J. Frisby Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit Br J Clin Pharmacol 60 2005 326 329
18. R.P. Riechelmann, M.K. Krzyzanowska, and A. O'Carroll Symptom and medication profiles among cancer patients attending a palliative care clinic Support Care Cancer 15 2007 1407 1412
19. R.P. Riechelmann, C. Zimmermann, and S.N. Chin Potential drug interactions in cancer patients receiving supportive care exclusively J Pain Symptom Manage 35 2008 535 543
20. J. Gaertner, K. Ruberg, and G. Schlesiger Drug interactions in palliative care - it's more than cytochrome P450 Palliat Med 26 2012 813 825
21. S. Frechen, A. Zoeller, and K. Ruberg Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany Drug Saf 35 2012 745 758
22. World Health Organization Cancer pain relief 1996 WHO Geneva
23. P. Klepstad, T. Fladvad, F. Skorpen European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care Research Network Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients Pain 152 2011 1139 1145
24. L. Brunton, J. Lazo, and K. Parker Goodman & Gilman's The pharmacological basis of therapeutics 11th ed 2006 The McGraw-Hill Companies, Inc. New York
25. R.P. Riechelmann, M.K. Krzyzanowska, and C. Zimmermann Futile medication use in terminally ill cancer patients Support Care Cancer 17 2009 745 748
26. A. Fede, M. Miranda, and D. Antonangelo Use of unnecessary medications by patients with advanced cancer: cross-sectional survey Support Care Cancer 19 2011 1313 1318
27. U.S. Food and Drug Administration. Professional Drug Information. Available from http://www.drugs.com. Accessed September 22, 2013.
28. U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available from http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed September 22, 2013.
29. Hansten P, Horn J. Hansten and Horn Drug Interactions. Available from http://www.hanstenandhorn.com. Accessed September 22, 2013.
30. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Available from http://medicine.iupui.edu/clinpharm/ddis/clinical-table/. Accessed September 22, 2013.
31. ® A Medication Safety Program of the Arizona Center for Education and Research on Therapeutics. QT Drugs. list. Available from http://www.azcert.org. Accessed May 13, 2014.
32. E.F. Wedam, G.E. Bigelow, and R.E. Johnson QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial Arch Intern Med 167 2007 2469 2475
33. S.A. Bernard, and E. Bruera Drug interactions in palliative care J Clin Oncol 18 2000 1780 1799
34. M.P. Davis, and J. Homsi The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine Support Care Cancer 9 2001 442 451
35. J. Lotsch, C. Skarke, and I. Tegeder Drug interactions with patient-controlled analgesia Clin Pharmacokinet 41 2002 31 57
36. A. Haddad, M. Davis, and R. Lagman The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions Support Care Cancer 15 2007 251 257
37. S.C. Armstrong, G.H. Wynn, and N.B. Sandson Pharmacokinetic drug interactions of synthetic opiate analgesics Psychosomatics 50 2009 169 176
38. T.B. Strouse Pharmacokinetic drug interactions in palliative care: focus on opioids J Palliat Med 12 2009 1043 1050
39. E.F. McCance-Katz, L.E. Sullivan, and S. Nallani Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review Am J Addict 19 2010 4 16
40. T.M. Polasek, F.P. Lin, and J.O. Miners Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment Br J Clin Pharmacol 71 2011 727 736
41. B.R. Overholser, and D.R. Foster Opioid pharmacokinetic drug-drug interactions Am J Manag Care 17 2011 S276 S287
42. J. Gudin Opioid therapies and cytochrome P450 interactions J Pain Symptom Manage 44 2012 S4 S14
43. C.F. Samer, Y. Daali, and M. Wagner Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety Br J Pharmacol 160 2010 919 930
44. M.F. Fromm, K. Eckhardt, and S. Li Loss of analgesic effect of morphine due to coadministration of rifampin Pain 72 1997 261 267
45. H. Sternbach The serotonin syndrome Am J Psychiatry 148 1991 705 713
46. E.W. Boyer, and M. Shannon The serotonin syndrome N Engl J Med 17 2005 1112 1120
47. R. Rastogi, R.A. Swarm, and T.A. Patel Case scenario: opioid association with serotonin syndrome: implications to the practitioners Anesthesiology 115 2011 1291 1298
48. N. Jackson, J. Doherty, and S. Coulter Neuropsychiatric complications of commonly used palliative care drugs Postgrad Med J 84 2008 121 126
49. A. Caraceni, G. Hanks, S. Kaasa European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC Lancet Oncol 13 2012 e58 e68
50. M.T. Fallon, and B.J. Laird A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project Palliat Med 25 2011 597 603
51. E.A. Laugsand, S. Kaasa, and P. Klepstad Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations Palliat Med 25 2011 442 453
52. N.S. Jecker, and R.A. Pearlman Medical futility. Who decides? Arch Intern Med 152 1992 1140 1144
53. C.P. Escalante, C.G. Martin, and L.S. Elting Medical futility and appropriate medical care in patients whose death is thought to be imminent Support Care Cancer 5 1997 274 280
54. V.E. von Gruenigen, and B.J. Daly Futility: clinical decisions at the end-of-life in women with ovarian cancer Gynecol Oncol 97 2005 638 644
55. J. Grönlund, T.I. Saari, and N.M. Hagelberg Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study Antimicrob Agents Chemother 55 2011 1063 1067
56. J. Grönlund, T.I. Saari, and N.M. Hagelberg Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Br J Clin Pharmacol 70 2010 78 87
57. C.F. Samer, Y. Daali, and M. Wagner The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone Br J Pharmacol 160 2010 907 918
58. E.D. Kharasch, D. Whittington, and C. Hoffer Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate Anesthesiology 101 2004 729 737
59. E.F. McCance-Katz, D.E. Moody, and S. Prathikanti Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients Drug Alcohol Depend 118 2011 326 334
60. R.D. Bruce, D.E. Moody, and W.B. Fang Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone Am J Drug Alcohol Abuse 37 2011 224 228
61. R.P. Kapil, A. Cipriano, and G.H. Michels Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system Clin Drug Investig 32 2012 583 592
62. J.T. Hanlon, K.E. Schmader, and G.P. Samsa A method for assessing drug therapy appropriateness J Clin Epidemiol 45 1992 1045 1051